Evaluation of ICP-B208 in Patients With Advanced Solid Tumors

Inclusion criteria

• 18 years old to 75 years old;
• Unresectable locally advanced or metastatic gastrointestinal tumors or other advanced solid tumors that have failed previous systemic treatment and have been confirmed by histopathology or cytology;
• The ECOG physical fitness score is 0 to 1 point.
• There is at least one measurable lesion;
• The organ function level must meet the prescribed standards;
• Effective contraceptive measures should be taken from the date of signing the informed consent form until at least 6 months after the use of the last dose of the study drug.
• Voluntarily enroll in the group and sign the informed consent form, and follow the trial treatment protocol and visit plan.

Exclusion criteria

• Other active malignant tumors occurred within 3 years before the first administration of the study drug;
• Received the anti-tumor treatment defined by the protocol within the time range before the first administration of the study drug specified in the protocol;
• Trial participants with unstable primary CNS tumors or CNS metastases;
• Uncontrollable or significant major cardiovascular diseases;
• Severe or uncontrollable systemic diseases; Or any unstable systemic disease;
• Active infection as defined in the plan;
• Have a history of severe allergic reactions to active pharmaceutical ingredients, non-active components in drugs or antibody drugs;
• Those who are known to have a history of alcohol abuse or drug abuse;
• Other circumstances that the researcher deems unsuitable for participation in this study.